source
- Edgewise Therapeutics' experimental heart drug meets Phase 2 endpoints in cardiomyopathy trialEdgewise Therapeutics reported that its oral candidate EDG-7500 achieved the predefined goals of a Phase 2 study in both obstructive and non‑obstructive hypertrophic cardiomyopathy. The trial demo…
- FDA gives modest backing to Moderna’s flu vaccine, noting efficacy questions but no major concernsThe FDA released briefing documents ahead of an advisory committee meeting on Moderna’s seasonal influenza vaccine. The agency’s assessment was described as tepid, highlighting some questions abou…